Cingulate (CING) Earnings growth forecast for next year

Cingulate Corp - graphic logo of issuer CING

Cingulate Inc. develops CNS drugs, demonstrating resilience to crises due to stable medical demand. Forward earnings per share dynamics help identify asset consolidation phases, while 17.50 captures the current state of the parameter. The company is implementing precision drug-release engineering systems for ADHD, although business success depends on clinical trial outcomes and strict liquidity management.

Cingulate Inc (CING): Expected net earnings per share growth next year from 07/04/2022 to 11/10/2026

CING (Cingulate): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Stock Price Cingulate Inc|CING - Consensus Target
- market capitalization details:
Market Capitalization Cingulate|CING - Value Adjusted for Debt and Cash
- book capitalization indicators:
Net Assets per Single Share Cingulate|CING - Total Stockholders' Equity|Market Capitalization to Book Value Ratio cingulate.com|CING - Cumulative Company Assets
- company total debt and liquidity indicators:
Total Debt to Capital Cingulate Inc.|CING - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Cingulate Inc|CING - Company Aggregate Debt|Debts to Book Capitalization Cingulate|CING - Long-Term Indebtedness|Company Current Liabilities Cingulate|Quick Liquidity cingulate.com
- net income and valuation ratios data:
CING - Company Net Income|Projected Future Earnings Cingulate Inc.|CING - P/E Multiple|Projected Price to Earnings Cingulate Inc|CING - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Cingulate|CING - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Cingulate|CING - Earnings per share for the trailing year|Quarterly EPS earnings growth cingulate.com|CING - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Cingulate Inc.
General company analysis:Cingulate Inc., CING
Finished products of Cingulate Inc

This indicator measures expected earnings momentum for the coming year, aggregating analyst forecasts to determine the trajectory of fundamental value. For Cingulate (CING), which is developing extended-release delivery systems for ADHD medications, changes in the consensus net income growth estimate reflect market confidence in the commercial success of its new formulations. A positive trend in this metric confirms the high investment attractiveness and the resilience of the company's business model.

Competitors of Cingulate Inc. (CING)

ALKS (Alkermes Inc.) - Earnings growth forecast for next year|Expected earnings per share growth for next year Avadel Corp (AVDL)|Earnings growth forecast for next year ATAI|GHRS (ghres.com) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year MindMed MNMD|COMPASS Pathways PLC (CMPS) - Expected net earnings per share growth next year|LB Pharma - Earnings growth forecast for next year|Bright Minds Corp (DRUG) - Expected earnings per share growth for next year|VNDA: Earnings growth forecast for next year|CYBN - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Alto Neuroscience|Projected earnings per share growth rate for next year NRXP (NRx Pharmaceuticals Inc.)|Earnings growth forecast for next year SILO|chinapharmaholdings.com (CPHI) - Net earnings per one share growth forecast for next year|Clearmind Medicine - Expected earnings per share growth for next year|Earnings growth forecast for next year pacificbayminerals.com PBM|SPRC - Net earnings per share growth forecast for next year|SEEL: Net earnings per share growth forecast for next year|VRPX: Earnings growth forecast for next year|Karuna Pharma (KRTX) - Earnings growth forecast for next year